PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
May 1, 2011, 00:00
10.1016/j.jval.2011.02.1061
https://www.valueinhealthjournal.com/article/S1098-3015(11)01200-9/fulltext
Title :
PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01200-9&doi=10.1016/j.jval.2011.02.1061
First page :
A192
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
546